PharmaEngine
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematol… Read more
PharmaEngine - Asset Resilience Ratio
PharmaEngine (4162) has an Asset Resilience Ratio of 62.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how PharmaEngine's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down PharmaEngine's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$3.09 Billion | 62.91% |
| Total Liquid Assets | NT$3.09 Billion | 62.91% |
Asset Resilience Insights
- Very High Liquidity: PharmaEngine maintains exceptional liquid asset reserves at 62.91% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
PharmaEngine Industry Peers by Asset Resilience Ratio
Compare PharmaEngine's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for PharmaEngine (2009–2024)
The table below shows the annual Asset Resilience Ratio data for PharmaEngine.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 49.03% | NT$2.87 Billion | NT$5.85 Billion | -20.58pp |
| 2023-12-31 | 69.61% | NT$2.75 Billion | NT$3.95 Billion | +21.90pp |
| 2022-12-31 | 47.71% | NT$1.89 Billion | NT$3.97 Billion | +6.41pp |
| 2021-12-31 | 41.30% | NT$1.66 Billion | NT$4.03 Billion | +4.27pp |
| 2020-12-31 | 37.03% | NT$1.56 Billion | NT$4.21 Billion | -54.17pp |
| 2019-12-31 | 91.20% | NT$3.32 Billion | NT$3.64 Billion | +5.30pp |
| 2018-12-31 | 85.90% | NT$3.30 Billion | NT$3.85 Billion | +20.16pp |
| 2017-12-31 | 65.74% | NT$2.70 Billion | NT$4.11 Billion | +13.52pp |
| 2016-12-31 | 52.23% | NT$2.07 Billion | NT$3.96 Billion | -31.76pp |
| 2015-12-31 | 83.98% | NT$2.72 Billion | NT$3.24 Billion | +79.02pp |
| 2010-12-31 | 4.96% | NT$4.72 Million | NT$95.27 Million | -50.08pp |
| 2009-12-31 | 55.04% | NT$23.00 Million | NT$41.79 Million | -- |